Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intarcia Therapeutics has signed definitive agreements with Quintiles for the global clinical development of Intarcia's ITCA 650 (DUROS continuous subcutaneous delivery of exenatide).
Subscribe to our email newsletter
The company claims that once developed and approved, ITCA 650 would be the first and only once-yearly injection-free GLP-1 therapy for the treatment of Type 2 diabetes that would help in glycemic control, weight loss and better tolerability.
Under the collaboration, Quintiles will support the development of ITCA 650 by its Capital Solutions group providing a combination of equity, product, and operational investments.
Intarcia Therapeutics executive chairman Kurt Graves said the deal would enforce their company besides accelerating the time-to-market for their injection-free GLP-1 therapy.
"Quintiles’ commitment and intellectual contributions in crafting this development alliance, plus their strategic investments in Intarcia, reflect our vision for ITCA 650 to reshape the way Type 2 diabetes is treated and to deliver significant treatment outcome advantages to patients, payors and providers," Graves added.